These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28715258)

  • 21. Isoniazid-resistant tuberculosis treatment with first-line drugs-Author reply.
    Menzies D
    Lancet Infect Dis; 2017 Mar; 17(3):260. PubMed ID: 28244386
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis.
    Sougakoff W
    Clin Microbiol Infect; 2011 Jun; 17(6):800-5. PubMed ID: 21682800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In reply: Acquired drug-resistance because of pharmacokinetic variability in a young child with tuberculosis.
    Garcia-Prats AJ; Donald PR; Schaaf HS
    Pediatr Infect Dis J; 2014 Nov; 33(11):1205-6. PubMed ID: 25361415
    [No Abstract]   [Full Text] [Related]  

  • 24. Multidrug resistance among persons with tuberculosis in California, 1994-2003.
    Granich RM; Oh P; Lewis B; Porco TC; Flood J
    JAMA; 2005 Jun; 293(22):2732-9. PubMed ID: 15941802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Cegielski JP; Nahid P; Sotgiu G
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 32198274
    [No Abstract]   [Full Text] [Related]  

  • 26. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?
    Tiberi S; D'Ambrosio L; Centis R; Migliori GB
    Int J Infect Dis; 2017 Dec; 65():133-134. PubMed ID: 29122690
    [No Abstract]   [Full Text] [Related]  

  • 27. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reply to comments by Kakkar and Dahiya.
    Chahine EB; Karaoui L; Mansour H
    Ann Pharmacother; 2014 May; 48(5):667. PubMed ID: 24733170
    [No Abstract]   [Full Text] [Related]  

  • 30. Better and safer treatment for multidrug-resistant tuberculosis.
    Farmer PE
    Lancet; 2018 Sep; 392(10150):798-800. PubMed ID: 30215368
    [No Abstract]   [Full Text] [Related]  

  • 31. [Reply to "Emergent strains of rifampicin-resistant Mycobacterium tuberculosis complex and susceptibility to isoniazid"].
    Vidal García M; Samper Blasco S; Monforte Cirac ML
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):73-4. PubMed ID: 25212828
    [No Abstract]   [Full Text] [Related]  

  • 32. Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.
    Prescrire Int; 2014 Oct; 23(153):245-6. PubMed ID: 25964976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoroquinolones resistance in multidrug-resistant tuberculosis in Pakistan and suitability of guidelines recommended standardized regimen.
    Ahmad N; Khan AH; Syed Sulaiman SA; Javaid A
    Int J Mycobacteriol; 2015 Sep; 4(3):258-9. PubMed ID: 27649876
    [No Abstract]   [Full Text] [Related]  

  • 34. Reducing harm in the treatment of multidrug-resistant tuberculosis.
    Reuter A; Furin J
    Lancet; 2018 Sep; 392(10150):797-798. PubMed ID: 30215367
    [No Abstract]   [Full Text] [Related]  

  • 35. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
    Balabanova Y; Fiebig L; Ignatyeva O; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
    Thorax; 2017 Sep; 72(9):850-852. PubMed ID: 28209653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.
    Alffenaar JC; Migliori GB; Gumbo T
    Lancet Infect Dis; 2017 Sep; 17(9):898. PubMed ID: 28845791
    [No Abstract]   [Full Text] [Related]  

  • 37. High rates of multidrug-resistant Mycobacterium tuberculosis in Sinaloa State, Mexico.
    Zazueta-Beltran J; Muro-Amador S; Flores-Gaxiola A; Llausas-Magaña E; León-Sicairos N; Canizalez-Roman A
    J Infect; 2007 Apr; 54(4):411-2. PubMed ID: 16730800
    [No Abstract]   [Full Text] [Related]  

  • 38. Multidrug-resistant tuberculosis and migration to Europe.
    van der Werf MJ; Hollo V; Ködmön C
    Clin Microbiol Infect; 2017 Aug; 23(8):578-579. PubMed ID: 28232165
    [No Abstract]   [Full Text] [Related]  

  • 39. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital.
    Weltman AC; Rose DN
    Arch Intern Med; 1994 Oct; 154(19):2161-7. PubMed ID: 7944836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. M/XDR-TB treatment perspective: How to avoid mountains of pills via digital technologies - Reply.
    Dheda K;
    Respirology; 2018 Jun; 23(6):637. PubMed ID: 29701301
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.